What are the recommended antibiotic regimens for treating community‑acquired pneumonia in adults across outpatient, inpatient, and intensive care settings?

Antibiotic Recommendations for Community-Acquired Pneumonia in Adults

For outpatients without comorbidities, use amoxicillin 1g every 8 hours or doxycycline 100mg twice daily; for those with comorbidities or recent antibiotic use, use a respiratory fluoroquinolone (levofloxacin 750mg daily, moxifloxacin 400mg daily) or a beta-lactam plus macrolide combination. 1

Outpatient Treatment Algorithm

Previously Healthy Patients (No Comorbidities)

First-line options:

• Amoxicillin 1g every 8 hours (strong recommendation based on inpatient efficacy data) 1
• Doxycycline 100mg twice daily (consider 200mg first dose for faster serum levels) 1
• Macrolide monotherapy (azithromycin, clarithromycin) - though increasingly questioned due to resistance 2

The 2019 ATS/IDSA guidelines prioritize amoxicillin based on demonstrated efficacy in inpatient studies, despite lack of atypical coverage. This represents a shift from older guidelines that emphasized macrolides. Doxycycline provides broader spectrum coverage including atypicals with a favorable safety profile.

Patients with Comorbidities or Risk Factors

Risk factors include: chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancies, immunosuppression, or antibiotic use within 3 months 2

Preferred regimens:

• Respiratory fluoroquinolone monotherapy: levofloxacin 750mg daily, moxifloxacin 400mg daily, or gemifloxacin 320mg daily (strong recommendation) 1, 2
• Beta-lactam plus macrolide combination:
  • High-dose amoxicillin (1g three times daily) OR amoxicillin-clavulanate (2g twice daily) PLUS
  • Azithromycin or clarithromycin 1, 2
  • Doxycycline can substitute for the macrolide 1

Important caveat: In regions with ≥25% high-level macrolide-resistant S. pneumoniae, avoid macrolide monotherapy even in healthy patients 2

Inpatient Non-ICU Treatment

Two equally effective options:

• Respiratory fluoroquinolone monotherapy (strong recommendation, level I evidence) 2
• Beta-lactam plus macrolide combination (strong recommendation, level I evidence) 2

Preferred beta-lactams: ceftriaxone, cefotaxime, or ampicillin; ertapenem for selected patients with gram-negative risk factors (excluding Pseudomonas) 2

For penicillin allergy: Use respiratory fluoroquinolone 2

ICU/Severe CAP Treatment

Standard severe CAP (no Pseudomonas or MRSA risk):

• Beta-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) PLUS azithromycin OR fluoroquinolone (strong recommendation) 2

The combination therapy is critical for severe CAP—multiple studies show improved mortality with dual coverage compared to monotherapy.

Special Pathogen Considerations

For Pseudomonas aeruginosa risk factors (structural lung disease, recent hospitalization, broad-spectrum antibiotic use):

• Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS
• Ciprofloxacin or levofloxacin 750mg OR
• Aminoglycoside plus azithromycin OR
• Aminoglycoside plus antipneumococcal fluoroquinolone 2

For MRSA risk factors (prior MRSA infection, IV drug use, recent influenza):

• Add vancomycin or linezolid to standard regimen 2

Duration of Therapy

Minimum 5 days of treatment, provided the patient:

• Is afebrile for 48-72 hours AND
• Has no more than 1 sign of clinical instability 2

This represents a shift from traditional 7-10 day courses. Longer duration needed only if initial therapy was inactive against the identified pathogen or extrapulmonary complications exist 2.

Key Clinical Pitfalls

Fluoroquinolone considerations: Despite FDA warnings about adverse events (tendon rupture, aortic dissection, peripheral neuropathy), the 2019 guidelines maintain fluoroquinolones as appropriate for CAP with comorbidities due to excellent efficacy, low resistance rates, and relative rarity of serious adverse events in this context 1. However, avoid in patients with history of these complications.

Macrolide resistance: Rising resistance rates mean macrolide monotherapy should be reserved only for previously healthy outpatients in low-resistance areas 2. When in doubt, use combination therapy or fluoroquinolone.

IV to oral transition: Switch when hemodynamically stable, clinically improving, able to ingest medications, and GI tract functioning normally—typically within first 3 days. No need for prolonged inpatient observation on oral therapy 2.

Recent evidence trends: A 2024 network meta-analysis found quinolones and macrolides most effective for clinical response, with quinolones showing trends toward lower mortality, though confidence intervals were broad 3. This supports guideline recommendations but emphasizes the need for more comparative trials.